Exelixis, Inc. EXEL
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Maintain current position; consider adding on weakness below 50 USD
Stable profitability and patent strength balance the delayed zanzalintinib launch and support a neutral stance.
Sentiment remains neutral with continued uncertainty around pipeline timelines after the delay.
HOLD is the call. Neutral is the market mood. Medium risk means some things can go wrong.
Latest change
- 30 Oct 2026 — The report shows stable profit generation that offsets the impact of the delayed zanzalintinib launch.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Exelixis is a biotech company focused on discovering and commercializing targeted cancer therapies. Its main product cabozantinib (CABOMETYX/COMETRIQ) generates strong revenues. The company has a growing pipeline led by zanzalintinib as the next potential growth driver.
Bull case
Strong profit generation and confirmed patent exclusivity for cabozantinib provide long-term support for the company.
Bear case
Delayed zanzalintinib launch and slower NET growth increase uncertainty around the growth trajectory.
Why this signal
Stable profitability and patent strength balance the delayed zanzalintinib launch and support a neutral stance.
Recent news
The Q3 report was released on 29 October 2026 with strong results and maintained full-year guidance. FDA extended the review of zanzalintinib + atezolizumab to PDUFA date 3 March 2027.